BR112021023254A2 - Métodos relacionados à tuberculose - Google Patents

Métodos relacionados à tuberculose

Info

Publication number
BR112021023254A2
BR112021023254A2 BR112021023254A BR112021023254A BR112021023254A2 BR 112021023254 A2 BR112021023254 A2 BR 112021023254A2 BR 112021023254 A BR112021023254 A BR 112021023254A BR 112021023254 A BR112021023254 A BR 112021023254A BR 112021023254 A2 BR112021023254 A2 BR 112021023254A2
Authority
BR
Brazil
Prior art keywords
tuberculosis
subject
related methods
infection
active
Prior art date
Application number
BR112021023254A
Other languages
English (en)
Inventor
Benjamin Swift
Catherine Rees
Original Assignee
Pbd Biotech Ltd
Univ Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pbd Biotech Ltd, Univ Nottingham filed Critical Pbd Biotech Ltd
Publication of BR112021023254A2 publication Critical patent/BR112021023254A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos relacionados à tuberculose. a invenção se refere a um método de diagnóstico de doença de tuberculose (tb) em um sujeito. o método compreende misturar um bacteriófago específico de mycobacteria com uma amostra de células mononucleares de sangue periférico (pbmcs) do sujeito, seguido por determinação da presença ou ausência de uma sequência de dna de mycobacteria em dna isolado da mistura. a invenção fornece um teste sensível e específico para a presença de tb incipiente, isto é, uma infecção assintomática com um alto risco de desenvolver tb ativa, ou para a presença de infecção de tuberculose latente (ltbi), isto é, uma infecção assintomática que não é provável de se desenvolver para tb ativa, em um sujeito.
BR112021023254A 2019-05-21 2020-03-05 Métodos relacionados à tuberculose BR112021023254A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907157.0A GB201907157D0 (en) 2019-05-21 2019-05-21 Methods
PCT/GB2020/050524 WO2020234555A1 (en) 2019-05-21 2020-03-05 Methods relating to tuberculosis

Publications (1)

Publication Number Publication Date
BR112021023254A2 true BR112021023254A2 (pt) 2022-02-08

Family

ID=67226285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023254A BR112021023254A2 (pt) 2019-05-21 2020-03-05 Métodos relacionados à tuberculose

Country Status (13)

Country Link
US (1) US20220243258A1 (pt)
JP (1) JP2022534370A (pt)
KR (1) KR20220024127A (pt)
CN (1) CN114072524A (pt)
AU (1) AU2020277711B2 (pt)
BR (1) BR112021023254A2 (pt)
CA (1) CA3141503A1 (pt)
EA (1) EA202192908A1 (pt)
GB (1) GB201907157D0 (pt)
MX (1) MX2021014201A (pt)
SG (1) SG11202112880QA (pt)
WO (1) WO2020234555A1 (pt)
ZA (1) ZA202109307B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092165A1 (en) * 2022-10-26 2024-05-02 The Administrators Of The Tulane Educational Fund Systems and methods for the automated diagnosis of mycobacterial infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776341B2 (en) * 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
CA2758124A1 (en) * 2008-04-19 2009-10-22 New York University Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
US8658350B2 (en) * 2008-09-22 2014-02-25 Oregon Health & Science University Methods for detecting Mycobacterium tuberculosis disease
US8058022B2 (en) * 2009-07-27 2011-11-15 Indian Institute Of Science Diagnosis and monitoring of mycobacterium tuberculosis infection
GB201213567D0 (en) * 2012-07-31 2012-09-12 Proteinlogic Ltd Biomarkers
US10344339B2 (en) 2013-10-01 2019-07-09 The University Of Nottingham Mycobacteria detection using bacteriophages
GB201401603D0 (en) * 2014-01-30 2014-03-19 Proteinlogic Ltd Biomarkers

Also Published As

Publication number Publication date
KR20220024127A (ko) 2022-03-03
WO2020234555A1 (en) 2020-11-26
MX2021014201A (es) 2022-02-21
JP2022534370A (ja) 2022-07-29
AU2020277711B2 (en) 2024-06-27
SG11202112880QA (en) 2021-12-30
EP3973078A1 (en) 2022-03-30
EA202192908A1 (ru) 2022-03-23
CA3141503A1 (en) 2020-11-26
US20220243258A1 (en) 2022-08-04
GB201907157D0 (en) 2019-07-03
ZA202109307B (en) 2023-04-26
AU2020277711A1 (en) 2022-01-06
CN114072524A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
Zhang et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals
Mandalakas et al. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis
Kunnath-Velayudhan et al. Immunodiagnosis of tuberculosis: a dynamic view of biomarker discovery
Dheda et al. T-cell interferon-γ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings
Casey et al. Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis
Cattamanchi et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis
Aggerbeck et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection
Nienhaus et al. Evaluation of the interferon-γ release assay in healthcare workers
Rose et al. QuantiFERON®-TB gold in-tube performance for diagnosing active tuberculosis in children and adults in a high burden setting
Boer et al. Mycobacterium bovis BCG vaccination induces divergent proinflammatory or regulatory T cell responses in adults
Heyckendorf et al. Tuberculosis treatment monitoring and outcome measures: new interest and new strategies
Krutikov et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis
Waggoner et al. Sensitive real-time PCR detection of pathogenic Leptospira spp. and a comparison of nucleic acid amplification methods for the diagnosis of leptospirosis
Walzl et al. Biomarkers for TB treatment response: challenges and future strategies
Kisuya et al. The diagnostic accuracy of Th1 (IFN-γ, TNF-α, and IL-2) and Th2 (IL-4, IL-6 and IL-10) cytokines response in AFB microscopy smear negative PTB-HIV co-infected patients
Marques Revisiting the Lyme disease serodiagnostic algorithm: the momentum gathers
Nemeth et al. Recruitment of Mycobacterium tuberculosis specific CD4+ T cells to the site of infection for diagnosis of active tuberculosis
Syed Ahamed Kabeer et al. Role of interferon gamma release assay in active TB diagnosis among HIV infected individuals
Sun et al. Potential role for Mycobacterium tuberculosis specific IL-2 and IFN-γ responses in discriminating between latent infection and active disease after long-term stimulation
Castro-Garza et al. Detection of anti-HspX antibodies and HspX protein in patient sera for the identification of recent latent infection by Mycobacterium tuberculosis
Gardiner et al. Transformative tools for tackling tuberculosis
Sebina et al. Circulating B-lymphocytes as potential biomarkers of tuberculosis infection activity
BR112015008042A2 (pt) diagnósticos complementares para terapia com inibidor de quinase da família tec
Herrmann et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis
Rangaka et al. Interferon release does not add discriminatory value to smear-negative HIV–tuberculosis algorithms